Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avandia, Actos Comparative Safety Evaluation "Not Novel," FDA Says

Executive Summary

FDA used the Avandia advisory committee to defend its view that marketing withdrawal decisions can be based on safety comparisons to other drugs approved for the same condition

You may also be interested in...



Avandia Shows FDA Discomfort With Meta-Analyses, Observational Studies In Decision-Making

The strong, continued resistance by FDA Center for Drug Evaluation and Research officials to rely on meta-analyses and observational studies as the basis for removing Avandia from the market suggests it will take time for the agency to become comfortable using the active surveillance system envisioned under the Sentinel Initiative in regulatory decision-making.

Avandia Shows FDA Discomfort With Meta-Analyses, Observational Studies In Decision-Making

The strong, continued resistance by FDA Center for Drug Evaluation and Research officials to rely on meta-analyses and observational studies as the basis for removing Avandia from the market suggests it will take time for the agency to become comfortable using the active surveillance system envisioned under the Sentinel Initiative in regulatory decision-making.

Avandia Advisory Committee Sees New Role For REMS As Research Tool

FDA advisory committee members who favor continued availability of GlaxoSmithKline's Avandia (rosiglitazone) with a Risk Evaluation and Mitigation Strategy seem to be hopeful the new regulatory tool can be used for an even broader purpose - providing answers needed to justify keeping the drug on the market

Related Content

Topics

UsernamePublicRestriction

Register

PS052444

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel